

Bijlage Zoekverantwoording

Onderzoeksvraag 1 (module Diagnostiek)

Hoe kan onderscheid worden gemaakt tussen koorts door infecties of tumorkoorts?

PIRT

Patients/Patiënten	Patiënt in de palliatieve fase met koorts, waarbij verdenking van tumorkoorts
Intervention/Interventie	Diagnostische test: CRP, BSE, procalcitonine, kweek, naproxentest, beeldvorming, zoals PET-scan of CT-scan
Reference test/Referentietest	Combinatie van diagnostische testen en klinische kenmerken
Target disorder/Ziektebeeld	Tumorkoorts vs. infectieuze koorts Parameters: sensitiviteit, specificiteit, PPV, NPV

Zoekstrategie

Ovid MEDLINE(R) <1946 to December 13, 2022>

- 1 fever/ or "fever of unknown origin"/ (46988)
- 2 fever\$.mp. (223267)
- 3 FUO.mp. (773)
- 4 or/1-3 (223282)
- 5 exp Neoplasms/ (3770900)
- 6 Neoplasm Staging/ (190952)
- 7 cancer\$.ti,ab. (1827156)
- 8 tumor\$.ti,ab. (1460427)
- 9 tumour\$.ti,ab. (270897)
- 10 carcinoma\$.ti,ab. (651181)
- 11 neoplas\$.ti,ab. (257341)
- 12 lymphoma.ti,ab. (158695)
- 13 melanoma.ti,ab. (113505)
- 14 staging.ti,ab. (78827)
- 15 metastas\$.ti,ab. (357972)
- 16 metastatic.ti,ab. (227113)
- 17 exp Neoplasm Metastasis/ (220007)
- 18 exp neoplastic processes/ (508061)
- 19 neoplastic process\$.ti,ab. (2882)
- 20 non small cell.ti,ab. (63965)
- 21 adenocarcinoma\$.ti,ab. (146281)
- 22 squamous cell.ti,ab. (107133)
- 23 nslc.ti,ab. (43941)
- 24 osteosarcoma\$.ti,ab. (23629)
- 25 phyllodes.ti,ab. (1903)
- 26 cystosarcoma\$.ti,ab. (569)
- 27 fibroadenoma\$.ti,ab. (3570)
- 28 (non adj small adj cell).ti,ab. (63965)
- 29 (non adj2 small adj2 cell).ti,ab. (64209)
- 30 (nonsmall adj2 cell).ti,ab. (3064)
- 31 plasmacytoma\$.ti,ab. (6215)
- 32 myeloma.ti,ab. (52176)
- 33 multiple myeloma.ti,ab. (37694)
- 34 lymphoblastoma\$.ti,ab. (345)
- 35 lymphocytoma\$.ti,ab. (335)
- 36 lymphosarcoma\$.ti,ab. (4074)

37 immunocytoma.ti,ab. (404)
38 sarcoma\$.ti,ab. (93787)
39 hodgkin\$.ti,ab. (63811)
40 (nonhodgkin\$ or non hodgkin\$).ti,ab. (36844)
41 malignan\$.ti,ab. (570610)
42 exp Paraneoplastic Syndromes/ (33764)
43 or/5-42 (4495619)
44 4 and 43 (31506)
45 naprosyn.mp. (72)
46 naproxen.mp. (6959)
47 Naproxen/ (4388)
48 C-Reactive Protein/ (53052)
49 crp.mp. (52483)
50 Blood Sedimentation/ (12419)
51 sedimentation.mp. (45802)
52 procalcitonin.mp. or Procalcitonin/ (7024)
53 exp Magnetic Resonance Imaging/ (522461)
54 magnetic resonance imag\$.mp. (557640)
55 chemical shift imaging.mp. (1002)
56 mr tomograph\$.mp. (516)
57 magnetization transfer contrast imaging.mp. (44)
58 proton spin tomograph\$.mp. (38)
59 zeugmatograph\$.mp. (35)
60 exp Magnetic Resonance Spectroscopy/ (221412)
61 exp MR Spectroscopy/ (221412)
62 exp NMR Tomography/ (522461)
63 exp NMR Imaging/ (522461)
64 MRS.mp. (21655)
65 MRI.mp. (258074)
66 NMR.mp. (153225)
67 KST.mp. (131)
68 or/53-67 (894427)
69 tomography, x-ray computed/ or four-dimensional computed tomography/ or exp tomography,
spiral computed/ (430511)
70 computer assisted tomography.mp. (813)
71 computed tomographic angiography.mp. (3285)
72 electron beam tomography.mp. (375)
73 high resolution compute? tomography.mp. (5593)
74 spiral computer assisted tomography.mp. (1)
75 69 or 70 or 71 or 72 or 73 or 74 (434259)
76 (detector? or slice? or slide? or row?).mp. (199274)
77 75 and 76 (19392)
78 Multidetector Computed Tomography/ (8136)
79 (msct or mdct).mp. (9399)
80 (multi slice? or multislice?).mp. (7756)
81 (multi row? or multirow?).mp. (206)
82 (multi slide? or multislide?).mp. (13)
83 (multi detect\$ or multidetect\$).mp. (17727)
84 (tomograph\$ adj5 (multi\$ or slice? or row? or slide? or detector?)).mp. (25897)
85 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 (44147)
86 deoxyglucose/ or deoxyglucose.tw. or desoxyglucose.tw. or deoxy-glucose.tw. or desoxy-
glucose.tw. or deoxy-d-glucose.tw. or desoxy-d-glucose.tw. or 2deoxyglucose.tw. or 2deoxy-d-
glucose.tw. or fluorodeoxyglucose.tw. or fluorodesoxyglucose.tw. or fludeoxyglucose.tw. or

fluorodeoxyglucose.tw. or fluordesoxyglucose.tw. or 18fluorodeoxyglucose.tw. or 18fluorodesoxyglucose.tw. or 18fluorodeoxyglucose.tw. or fdg*.tw. or 18fdg*.tw. or 18f-dg*.tw. or Fluorodeoxyglucose F18/ (60512)

87 (fluor or 2fluor* or fluoro or fluorodeoxy or fludeoxy or fluorine or 18f or 18flu*).tw. (55784)

88 glucose.tw. (475225)

89 87 and 88 (9161)

90 86 or 89 (61157)

91 (pet or petscan*).tw. or tomography, emission-computed/ (110979)

92 emission.tw. (161425)

93 (tomograph or tomographs or tomographic* or tomography or tomographies).tw. (403156)

94 92 and 93 (73938)

95 91 or 94 (139840)

96 90 and 95 (42784)

97 Positron-Emission Tomography/ (61604)

98 96 or 97 (80669)

99 animals/ not humans/ (5040958)

100 98 not 99 (74736)

101 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 68 or 85 or 100 (1109842)

102 44 and 101 (3209)

Ovid MEDLINE(R) Epub Ahead of Print <December 13, 2022>, Ovid MEDLINE(R) Daily Update <December 13, 2022>

1 fever/ or "fever of unknown origin"/ (85)

2 fever\$.mp. (2304)

3 F.U.O.mp. (15)

4 or/1-3 (2304)

5 exp Neoplasms/ (7495)

6 Neoplasm Staging/ (140)

7 cancer\$.ti,ab. (32083)

8 tumor\$.ti,ab. (20068)

9 tumour\$.ti,ab. (2736)

10 carcinoma\$.ti,ab. (7640)

11 neoplas\$.ti,ab. (3266)

12 lymphoma.ti,ab. (2100)

13 melanoma.ti,ab. (1497)

14 staging.ti,ab. (1313)

15 metastas\$.ti,ab. (5421)

16 metastatic.ti,ab. (3480)

17 exp Neoplasm Metastasis/ (147)

18 exp neoplastic processes/ (685)

19 neoplastic process\$.ti,ab. (25)

20 non small cell.ti,ab. (1312)

21 adenocarcinoma\$.ti,ab. (2066)

22 squamous cell.ti,ab. (1861)

23 nscl.ti,ab. (953)

24 osteosarcoma\$.ti,ab. (296)

25 phyllodes.ti,ab. (23)

26 cystosarcoma\$.ti,ab. (2)

27 fibroadenoma\$.ti,ab. (73)

28 (non adj small adj cell).ti,ab. (1312)

29 (non adj2 small adj2 cell).ti,ab. (1315)

30 (nonsmall adj2 cell).ti,ab. (49)

31 plasmacytoma\$.ti,ab. (49)

- 32 myeloma.ti,ab. (633)
- 33 multiple myeloma.ti,ab. (569)
- 34 lymphoblastoma\$.ti,ab. (0)
- 35 lymphocytoma\$.ti,ab. (6)
- 36 lymphosarcoma\$.ti,ab. (1)
- 37 immunocytoma.ti,ab. (1)
- 38 sarcoma\$.ti,ab. (1036)
- 39 hodgkin\$.ti,ab. (565)
- 40 (nonhodgkin\$ or non hodgkin\$).ti,ab. (344)
- 41 malignan\$.ti,ab. (8131)
- 42 exp Paraneoplastic Syndromes/ (28)
- 43 or/5-42 (52395)
- 44 4 and 43 (275)
- 45 naprosyn.mp. (1)
- 46 naproxen.mp. (59)
- 47 Naproxen/ (6)
- 48 C-Reactive Protein/ (124)
- 49 crp.mp. (1003)
- 50 Blood Sedimentation/ (6)
- 51 sedimentation.mp. (342)
- 52 procalcitonin.mp. or Procalcitonin/ (161)
- 53 exp Magnetic Resonance Imaging/ (929)
- 54 magnetic resonance imag\$.mp. (5594)
- 55 chemical shift imaging.mp. (7)
- 56 mr tomograph\$.mp. (0)
- 57 magnetization transfer contrast imaging.mp. (1)
- 58 proton spin tomograph\$.mp. (0)
- 59 zeugmatograph\$.mp. (0)
- 60 exp Magnetic Resonance Spectroscopy/ (162)
- 61 exp MR Spectroscopy/ (162)
- 62 exp NMR Tomography/ (929)
- 63 exp NMR Imaging/ (929)
- 64 MRS.mp. (610)
- 65 MRI.mp. (6266)
- 66 NMR.mp. (2189)
- 67 KST.mp. (5)
- 68 or/53-67 (11561)
- 69 tomography, x-ray computed/ or four-dimensional computed tomography/ or exp tomography, spiral computed/ (402)
- 70 computer assisted tomography.mp. (0)
- 71 computed tomographic angiography.mp. (41)
- 72 electron beam tomography.mp. (2)
- 73 high resolution compute? tomography.mp. (83)
- 74 spiral computer assisted tomography.mp. (0)
- 75 69 or 70 or 71 or 72 or 73 or 74 (521)
- 76 (detector? or slice? or slide? or row?).mp. (2531)
- 77 75 and 76 (36)
- 78 Multidetector Computed Tomography/ (4)
- 79 (msct or mdct).mp. (64)
- 80 (multi slice? or multislice?).mp. (88)
- 81 (multi row? or multirow?).mp. (0)
- 82 (multi slide? or multislide?).mp. (0)
- 83 (multi detect\$ or multidetect\$).mp. (133)

84 (tomograph\$ adj5 (multi\$ or slice? or row? or slide? or detector?)).mp. (320)
85 77 or 78 or 79 or 80 or 81 or 82 or 83 or 84 (450)
86 deoxyglucose/ or deoxyglucose.tw. or desoxyglucose.tw. or deoxy-glucose.tw. or desoxy-glucose.tw. or deoxy-d-glucose.tw. or desoxy-d-glucose.tw. or 2deoxyglucose.tw. or 2deoxy-d-glucose.tw. or fluorodeoxyglucose.tw. or fluorodesoxyglucose.tw. or fludeoxyglucose.tw. or fluordeoxyglucose.tw. or fluordesoxyglucose.tw. or 18fluorodeoxyglucose.tw. or 18fluorodesoxyglucose.tw. or fdg*.tw. or 18fdg*.tw. or 18f-dg*.tw. or Fluorodeoxyglucose F18/ (872)
87 (fluor or 2fluor* or fluoro or fluorodeoxy or fludeoxy or fluorine or 18f or 18flu*).tw. (1449)
88 glucose.tw. (5763)
89 87 and 88 (172)
90 86 or 89 (886)
91 (pet or petscan*).tw. or tomography, emission-computed/ (2637)
92 emission.tw. (4323)
93 (tomograph or tomographs or tomographic* or tomography or tomographies).tw. (7969)
94 92 and 93 (1901)
95 91 or 94 (3226)
96 90 and 95 (807)
97 Positron-Emission Tomography/ (130)
98 96 or 97 (888)
99 animals/ not humans/ (5888)
100 98 not 99 (874)
101 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 68 or 85 or 100 (14024)
102 44 and 101 (36)

Embase

#1.	'fever'/exp	309565
#2.	'pyrexia idiopathica'/exp	6773
#3.	fever*:ti,ab	284202
#4.	fuo:ti,ab	1522
#5.	#1 OR #2 OR #3 OR #4	454385
#6.	'neoplasm'/exp	5828741
#7.	'cancer staging'/exp	425801
#8.	cancer*:ti,ab	3034517
#9.	tumor*:ti,ab	2299852
#10.	tumour*:ti,ab	422705
#11.	carcinoma*:ti,ab	1009800
#12.	lymphoma:ti,ab	267044
#13.	melanoma:ti,ab	182037
#14.	staging:ti,ab	148042
#15.	metastatic:ti,ab	42278
#16.	'metastasis'/exp	781398
#17.	'oncogenesis and malignant transformation'/exp	1184938
#18.	neoplastic AND process*:ti,ab	17682
#19.	(non NEAR/1 small NEAR/1 cell):ti,ab	126104
#20.	adenocarcinoma*:ti,ab	259577
#21.	(squamous NEAR/1 cell):ti,ab	174436

#22.	nsclc:ti,ab	103023
#23.	osteosarcoma*:ti,ab	35253
#24.	phyllodes:ti,ab	2998
#25.	cystosarcoma*:ti,ab	685
#26.	fibroadenoma*:ti,ab	5479
#27.	(non NEAR/2 small NEAR/2 cell):ti,ab	126348
#28.	(nonsmall NEAR/2 cell):ti,ab	105164
#29.	plasmacytoma*:ti,ab	8761
#30.	myeloma:ti,ab	97765
#31.	(multiple NEAR/1 myeloma):ti,ab	77060
#32.	lymphoblastoma*:ti,ab	346
#33.	lymphocytoma*:ti,ab	432
#34.	lymphosarcoma*:ti,ab	4586
#35.	immunocytoma:ti,ab	472
#36.	sarcoma*:ti,ab	137001
#37.	hodgkin*:ti,ab	104118
#38.	nonhodgkin*:ti,ab OR ((non NEAR/1 hodgkin*):ti,ab)	62005
#39.	malignan*:ti,ab	953232
#40.	'paraneoplastic syndrome'/exp	49354
#41.	#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40	6935917
#42.	#5 AND #41	117648
#43.	naproxen:ti,ab	9483
#44.	naprosyn:ti,ab	110
#45.	'naproxen'/exp	28928
#46.	'c reactive protein'/exp	237255
#47.	crp:ti,ab	121064
#48.	'erythrocyte sedimentation rate'/exp	61987
#49.	ers:ti,ab OR sedimentation:ti,ab	74982
#50.	'procalcitonin'/exp	21370
#51.	procalcitonin:ti,ab	13718
#52.	#43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51	397739
#53.	nuclear magnetic resonance imaging'/exp OR 'nuclear magnetic resonance spectroscopy'/exp OR 'nuclear magnetic resonance'/exp	1583925
#54.	(magnetic NEAR/1 resonance NEAR/1 imag*):ti,ab	343427
#55.	(chemical NEAR/1 shift NEAR/1 imaging):ti,ab	1243
#56.	(mr NEAR/1 tomograph*):ti,ab	692
#57.	(magnetization NEAR/1 transfer NEAR/1 contrast NEAR/1 imaging):ti,ab	30
#58.	(proton NEAR/1 spin NEAR/1 tomograph*):ti,ab	12
#59.	zeugmatograph*:ti,ab	39
#60.	mrs:ti,ab OR mri:ti,ab OR kst:ti,ab OR nmr:ti,ab	760852

#61.	#53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60	1696296
#62.	'x-ray computed tomography'/exp	93655
#63.	'four dimensional computed tomography'/exp	5384
#64.	'spiral computer assisted tomography'/exp	12935
#65.	(computer NEAR/1 assisted NEAR/1 tomography):ti,ab	548
#66.	(computed NEAR/1 tomographic NEAR/1 angiography):ti,ab	4750
#67.	(electron NEAR/1 beam NEAR/1 tomography):ti,ab	429
#68.	(high NEAR/1 resolution NEAR/1 compute? NEAR/1 tomography):ti,ab	909
#69.	(spiral NEAR/1 computer NEAR/1 assisted NEAR/1 tomography):ti,ab	4
#70.	#62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69	125718
#71.	detector?:ti,ab OR slice?:ti,ab OR slide?:ti,ab OR row?:ti,ab	177066
#72.	#70 AND #71	1957
#73.	'multidetector computed tomography'/exp	37778
#74.	msct:ti,ab OR mdct:ti,ab	17459
#75.	((multi NEAR/1 slice?):ti,ab) OR multislice?:ti,ab	189
#76.	((multi NEAR/1 row?):ti,ab) OR multirow?:ti,ab	7
#77.	((multi NEAR/1 slide?):ti,ab) OR multislide?:ti,ab	11
#78.	((multi NEAR/1 detect*):ti,ab) OR multidetect*:ti,ab	18911
#79.	(tomograph* NEAR/5 (multi* OR slice? OR row? OR slide? OR detector?)):ti,ab	29114
#80.	#72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79	58870
#81.	'deoxyglucose'/exp	12176
#82.	'fluorodeoxyglucose f 18'/exp	72388
#83.	deoxyglucose:ti,ab OR desoxyglucose:ti,ab OR 'deoxy-glucose':ti,ab OR 'desoxy-glucose':ti,ab OR 'deoxy-d-glucose':ti,ab OR 'desoxy-d-glucose':ti,ab OR 2deoxyglucose:ti,ab OR '2deoxy-d-glucose':ti,ab OR fluorodeoxyglucose:ti,ab OR fluorodesoxyglucose:ti,ab OR fludeoxyglucose:ti,ab OR fluordeoxyglucose:ti,ab OR fluordesoxyglucose:ti,ab OR 18fluorodeoxyglucose:ti,ab OR 18fluordesoxyglucose:ti,ab OR 18fluorodeoxyglucose:ti,ab OR fdg*:ti,ab OR 18fdg*:ti,ab OR '18f dg*':ti,ab	96607
#84.	fluor:ti,ab OR 2fluor*:ti,ab OR fluoro:ti,ab OR fluorodeoxy:ti,ab OR fludeoxy:ti,ab OR fluorine:ti,ab OR 18f:ti,ab OR 18flu*:ti,ab	80649
#85.	glucose:ti,ab	715388
#86.	#84 AND #85	12293
#87.	#81 OR #82 OR #83 OR #86	123397
#88.	'computer assisted emission tomography'/exp	296003
#89.	pet:ti,ab OR petscan*:ti,ab	207669
#90.	emission:ti,ab	265427
#91.	tomograph:ti,ab OR tomographs:ti,ab OR tomographic*:ti,ab OR tomography:ti,ab OR tomographies:ti,ab	618579
#92.	#90 AND #91	113455
#93.	#88 OR #89 OR #92	37266
#94.	#87 AND #93	101654
#95.	#52 OR #61 OR #80 OR #94	2177860
#96.	#42 AND #95 AND ([article]/lim OR [article in press]/lim OR [review]/lim) AND ([dutch]/lim OR [english]/lim) AND ([embase]/lim OR [pubmed-not-medline]/lim)	14684

#97.	sensitiv*:ti,ab OR detect*:ti,ab OR accura*:ti,ab OR specific*:ti,ab OR reliab*:ti,ab OR positive:ti,ab OR negative:ti,ab OR diagnos*:ti,ab	13821086
#98.	#96 AND #97 AND [humans]/lim	9177

Cochrane Library

- #1 MeSH descriptor: [Fever] explode all trees 2223
- #2 MeSH descriptor: [Fever of Unknown Origin] explode all trees 67
- #3 fever*:ti,ab 15335
- #4 FUO:ti,ab 58
- #5 {or #1-#4} 16292
- #6 MeSH descriptor: [Neoplasms] explode all trees 90536
- #7 MeSH descriptor: [Neoplasm Staging] explode all trees 6886
- #8 cancer*:ti,ab 167181
- #9 tumor*:ti,ab 61672
- #10 tumour*:ti,ab 13784
- #11 carcinoma*:ti,ab 33567
- #12 neoplasm*:ti,ab 7823
- #13 lymphoma:ti,ab 10169
- #14 melanoma:ti,ab 5692
- #15 staging:ti,ab 5718
- #16 metastas*:ti,ab 20116
- #17 metastatic:ti,ab 31362
- #18 MeSH descriptor: [Neoplasm Metastasis] explode all trees 5515
- #19 MeSH descriptor: [Neoplastic Processes] explode all trees 10538
- #20 neoplastic process*:ti,ab 181
- #21 (non NEAR small NEAR cell):ti,ab 12895
- #22 adenocarcinoma*:ti,ab 9214
- #23 (squamous NEAR cell):ti,ab 8100
- #24 nsclc:ti,ab 10868
- #25 osteosarcoma*:ti,ab 472
- #26 phyllodes:ti,ab 4
- #27 cystosarcoma*:ti,ab 0
- #28 fibroadenoma*:ti,ab 91
- #29 (non NEAR/2 small NEAR/2 cell):ti,ab 12868
- #30 (nonsmall NEAR/2 cell):ti,ab 10138
- #31 plasmacytoma*:ti,ab 112
- #32 myeloma:ti,ab 5930
- #33 (multiple NEAR myeloma):ti,ab 5372
- #34 lymphoblastoma*:ti,ab 0
- #35 lymphocytoma*:ti,ab 1
- #36 lymphosarcoma*:ti,ab 23
- #37 immunocytoma:ti,ab 16
- #38 sarcoma*:ti,ab 2631
- #39 hodgkin*:ti,ab 5532
- #40 (nonhodgkin* or (non NEAR hodgkin*)):ti,ab 3344
- #41 malignan*:ti,ab 27963
- #42 MeSH descriptor: [Paraneoplastic Syndromes] explode all trees 313
- #43 {or #6-#42} 257834
- #44 #5 AND #43 3232
- #45 (naprosyn OR naproxen):ti,ab 2295
- #46 MeSH descriptor: [Naproxen] explode all trees 1188
- #47 MeSH descriptor: [C-Reactive Protein] explode all trees 5042

#48 crp:ti,ab 20733

#49 MeSH descriptor: [Blood Sedimentation] explode all trees 525

#50 sedimentation:ti,ab 2625

#51 MeSH descriptor: [Procalcitonin] explode all trees 55

#52 procalcitonin:ti,ab 1217

#53 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees 9034

#54 (magnetic NEAR resonance NEAR imag*):ti,ab 15923

#55 (chemical NEAR shift NEAR imaging):ti,ab 32

#56 (mr NEAR tomograph*):ti,ab 101

#57 (magnetization NEAR transfer NEAR contrast NEAR imaging):ti,ab 4

#58 (proton NEAR spin NEAR tomograph*):ti,ab 2

#59 zeugmatograph*:ti,ab 0

#60 MeSH descriptor: [Magnetic Resonance Spectroscopy] explode all trees 746

#61 MeSH descriptor: [Magnetic Resonance Spectroscopy] explode all trees 746

#62 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees 9034

#63 (MRI OR MRS OR NMR OR KST):ti,ab 34234

#64 {or #53-#63} 43168

#65 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees 5629

#66 MeSH descriptor: [Four-Dimensional Computed Tomography] explode all trees 17

#67 MeSH descriptor: [Tomography, Spiral Computed] explode all trees 343

#68 (computer NEAR assisted NEAR tomography):ti,ab 46

#69 (computed NEAR tomographic NEAR angiography):ti,ab 341

#70 (electron NEAR beam NEAR tomography):ti,ab 65

#71 (high NEAR resolution NEAR compute? NEAR tomography):ti,ab 573

#72 (spiral NEAR computer NEAR assisted NEAR tomography):ti,ab 0

#73 {or #65-#72} 6408

#74 (detector? or slice? or slide? or row?):ti,ab 7251

#75 #73 AND #74 432

#76 MeSH descriptor: [Multidetector Computed Tomography] explode all trees 163

#77 (msct or mdct):ti,ab 512

#78 ((multi NEAR slice?) or multislice?):ti,ab 392

#79 ((multi NEAR row?) or multirow?):ti,ab 80

#80 ((multi NEAR slide?) or multislide?):ti,ab 3

#81 ((multi NEAR detect*) or multidetect*):ti,ab 670

#82 (tomograph* NEAR/5 (multi* or slice? or row? or slide? or detector?)):ti,ab 839

#83 {or #75-#82} 1797

#84 MeSH descriptor: [Deoxyglucose] explode all trees 717

#85 MeSH descriptor: [Fluorodeoxyglucose F18] explode all trees 661

#86 (deoxyglucose or desoxyglucose or "deoxy-glucose" or "desoxy-glucose" or "deoxy-d-glucose" or "desoxy-d-glucose" or 2deoxyglucose or "2deoxy-d-glucose" or fluorodeoxyglucose or fluorodesoxyglucose or fludeoxyglucose or fluordeoxyglucose or fluordesoxyglucose or 18fluorodeoxyglucose or 18fluordesoxyglucose or 18fluordeoxyglucose or fdg* or 18fdg* or 18fdg*):ti,ab 2824

#87 (fluor or 2fluor* or fluoro or fluorodeoxy or fludeoxy or fluorine or 18f or 18flu*):ti,ab 2484

#88 glucose:ti,ab 64140

#89 #87 AND #88 512

#90 #84 OR #85 OR #86 OR #89 2961

#91 MeSH descriptor: [Tomography, Emission-Computed] explode all trees 2659

#92 (pet or petscan*):ti,ab 8120

#93 emission:ti,ab 5223

#94 (tomograph or tomographs or tomographic* or tomography or tomographies):ti,ab 22149

#95 #93 AND #94 4384

#96 #91 OR #92 OR #95 10699

#97 #90 AND #96 2778
 #98 MeSH descriptor: [Positron-Emission Tomography] explode all trees 1160
 #99 #97 OR #98 3405
 #100 #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 OR #64 OR #83 OR #9974314
 #101 #44 AND #100 194

Tabel 7. Resultaten van zoekactie van onderzoeksvraag 3

Database	Aantal
Medline	3209
PreMedline	36
Embase	9177
CDSR	2
CENTRAL	192
Totaal aantal resultaten	12616
Aantal geëxcludeerd (dubbelen en foute taal)	2007
Totaal aantal unieke resultaten	10609

Tabel 8. Overzicht van geëxcludeerde studies gebaseerd op beoordeling van de volledige tekst van onderzoeksvraag 3

Referentie	Reden voor exclusie
Abrahamsson, J., M. Pålman, and L. Mallander, Interleukin 6, but not tumour necrosis factor- α , is a good predictor of severe infection in febrile neutropenic and non-neutropenic children with malignancy. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1997. 86(10): p. 1059-1064.	Kinderen
Ahn, S., et al., Predictive factors of bacteraemia in low-risk patients with febrile neutropenia. <i>Emergency Medicine Journal</i> , 2012. 29(9): p. 715-9.	Selectiecriteria primair gericht op neutropene koorts
Ahn, S., et al., Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. <i>Supportive Care in Cancer</i> , 2011. 19(8): p. 1151-8.	Outcome is niet diagnose van tumor- of infectiekoorts
AlAzmi, A., et al., A clinical approach to non-neutropenic fever in children with cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2021. 27(3): p. 560-569.	Kinderen
Alsirafy, S.A., et al., Naproxen test for neoplastic fever may reduce suffering. <i>Journal of Palliative Medicine</i> , 2011. 14(5): p. 665-7.	Case report
Ammann, R.A., et al., Identification of children presenting with fever in chemotherapy-induced neutropenia at low risk for severe bacterial infection. <i>Medical and Pediatric Oncology</i> , 2003. 41(5): p. 436-443.	Kinderen
Arber, C., et al., C-reactive protein and fever in neutropenic patients. <i>Scandinavian Journal of Infectious Diseases</i> , 2000. 32(5): p. 515-20.	Geen 2x2 tabellen mogelijk
Arif, T. and R.S. Phillips, Updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment and management of fever during neutropenia in children with cancer. <i>Pediatric Blood & Cancer</i> , 2019. 66(10): p. e27887.	Kinderen
Avabratha, K.S., et al., Significance of C-reactive protein during febrile neutropenia in pediatric malignancies. <i>Indian Pediatrics</i> , 2009. 46(9): p. 797-9.	Kinderen
Badurdeen, S., et al., Elevated serum cytokine levels using cytometric bead arrays predict culture-positive infections in childhood oncology patients with febrile neutropenia. <i>Journal of Pediatric Hematology/Oncology</i> , 2012. 34(1): p. e36-8.	Kinderen

Baraka, A. and M. Zakaria, Presepsin as a diagnostic marker of bacterial infections in febrile neutropenic pediatric patients with hematological malignancies. <i>International Journal of Hematology</i> , 2018. 108(2): p. 184-191.	Kinderen
Bilgir, O., et al., Comparative levels of macrophage migration inhibitory factor, procalcitonin, osteoprotegerin, interleukin-8, hs-C reactive protein, D-dimer in febrile neutropenia, newly diagnosed cancer patients, and infectious fever. <i>Transfusion & Apheresis Science</i> , 2012. 46(1): p. 19-24.	Geen 2x2 tabellen mogelijk
Bruno, B., et al., Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients. <i>Expert Review of Hematology</i> , 2017. 10(6): p. 543-550.	Narrative review
Buyukberber, N., et al., Cytokine concentrations are not predictive of bacteremia in febrile neutropenic patients. <i>Medical Oncology</i> , 2009. 26(1): p. 55-61.	Geen 2x2 tabellen mogelijk
Camus, V., et al., 18F-FDG-PET/CT imaging in patients with febrile neutropenia and haematological malignancies. <i>Anticancer Research</i> , 2015. 35(5): p. 2999-3006.	Selectiecriteria primair gericht op neutropene koorts
Carcò, D., et al., C-Reactive Protein Monitoring and Clinical Presentation of Fever as Predictive Factors of Prolonged Febrile Neutropenia and Blood Culture Positivity after Autologous Hematopoietic Stem Cell Transplantation—Single-Center Real-Life Experience. <i>Journal of Clinical Medicine</i> , 2022. 11(2).	Na autologe stamcel transplantatie
Carnino, L., et al., Procalcitonin as a predictive marker of infections in chemotherapy-induced neutropenia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010. 136(4): p. 611-615.	Geen koorts
Casl, M.T., et al., The differential diagnostic capacity of serum amyloid A protein between infectious and non-infectious febrile episodes of neutropenic patients with acute leukemia. <i>Leukemia Research</i> , 1994. 18(9): p. 665-70.	Geen 2x2 tabellen mogelijk
Chaftari, A.M., et al., Role of procalcitonin and interleukin-6 in predicting cancer, and its progression independent of infection. <i>PLoS ONE</i> , 2015. 10(7).	Outcome is niet diagnose van tumor- of infectiekoorts
Chang, J.C. and H.B. Hawley, Neutropenic fever of undetermined origin (N-FUO): why not use the naproxen test? <i>Cancer Investigation</i> , 1995. 13(4): p. 448-50.	Narrative review
Chang, J.C., Neoplastic fever. A proposal for diagnosis. <i>Archives of Internal Medicine</i> , 1989. 149(8): p. 1728-30.	Narrative review
Chang, J.C., NSAID test to distinguish between infectious and neoplastic fever in cancer patients. <i>Postgraduate Medicine</i> , 1988. 84(8): p. 71-2.	Narrative review
Chaudhary, N., et al., Significance of interleukin-6 (IL-6) and C-reactive protein (CRP) in children and young adults with febrile neutropenia during chemotherapy for cancer: a prospective study. <i>Journal of Pediatric Hematology/Oncology</i> , 2012. 34(8): p. 617-23.	Kinderen
Chen, J., et al., Diagnostic models for fever of unknown origin based on 18F-FDG PET/CT: a prospective study in China. <i>EJNMMI Research</i> , 2022. 12(1).	FUO, niet enkel kanker
Çiledağ, N., et al., The role of multidetector computed tomography in the early diagnosis of invasive pulmonary aspergillosis in patients with febrile neutropenia undergoing hematopoietic stem cell transplantation. <i>Turkish Journal of Hematology</i> , 2012. 29(1): p. 28-33.	Selectiecriteria primair gericht op neutropene koorts
Coşkun, O., et al., The value of naproxen test as a diagnostic method to differentiate cause of fever. <i>TAF Preventive Medicine Bulletin</i> , 2012. 11(6): p. 779-782.	Geen 2x2 tabellen mogelijk
Dabbous, H.K., F.A. Ali-Eldin, and I.M.F. Montasser, Role of procalcitonin in diagnosis of bacterial infection in trans-arterial chemoembolisation treated hepatocellular carcinoma patients. <i>Arab Journal of Gastroenterology</i> , 2015. 16(1): p. 10-13.	Koorts na interventie

De Bont, E.S., et al., Interpretation of inflammatory markers in feverish cancer patients with or without neutropenia at admission. <i>British Journal of Haematology</i> , 2001. 114(2): p. 489-91.	Letter
de Bont, E.S., et al., Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. <i>British Journal of Haematology</i> , 1999. 107(2): p. 375-80.	Geen 2x2 tabellen mogelijk
de Bont, E.S., et al., Procalcitonin: a diagnostic marker of bacterial infection in neutropenic cancer patients with fever? <i>Infection</i> , 2000. 28(6): p. 398-400.	Selectie criterium primair gericht op neutropene koorts
Delebarre, M., et al., Which Variables Are Useful for Predicting Severe Infection in Children With Febrile Neutropenia? <i>Journal of Pediatric Hematology/Oncology</i> , 2015. 37(8): p. e468-74.	Kinderen
Demirkaya, M., et al., Adrenomedullin--A New Marker in Febrile Neutropenia: Comparison With CRP and Procalcitonin. <i>Pediatric Hematology & Oncology</i> , 2015. 32(7): p. 482-9.	Kinderen
Diepold, M., et al., Performance of Interleukin-6 and Interleukin-8 serum levels in pediatric oncology patients with neutropenia and fever for the assessment of low-risk. <i>BMC Infectious Diseases</i> , 2008. 8: p. 28.	Kinderen
Dornbusch, H.J., et al., Non-infectious causes of elevated procalcitonin and C-reactive protein serum levels in pediatric patients with hematologic and oncologic disorders. <i>Supportive Care in Cancer</i> , 2008. 16(9): p. 1035-1040.	Kinderen
Douglas, A., et al., [18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. <i>The Lancet Haematology</i> , 2022. 9(8): p. e573-e584.	Foute uitkomsten
Durnaś, B., et al., Utility of blood procalcitonin concentration in the management of cancer patients with infections. <i>OncoTargets and Therapy</i> , 2016. 9: p. 469-475.	Narrative review
Economos, K., et al., The effect of naproxen on fever in patients with advanced gynecologic malignancies. <i>Gynecologic Oncology</i> , 1995. 56(2): p. 250-4.	Reeds geselecteerde populatie (negatieve culturen en Rx thorax)
El Haddad, H., et al., Biomarkers of Sepsis and Bloodstream Infections: The Role of Procalcitonin and Proadrenomedullin With Emphasis in Patients With Cancer. <i>Clinical Infectious Diseases</i> , 2018. 67(6): p. 971-977.	Narrative review
El-Maghraby, S.M., et al., The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies. <i>Journal of Pediatric Hematology/Oncology</i> , 2007. 29(3): p. 131-6.	Kinderen
Elshalakani, M.O.M., et al., Diagnostic value of FDG-PET/CT in fever of unknown origin. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2022. 53(1).	FUO, niet enkel kanker
Engel, A., et al., An analysis of interleukin-8, interleukin-6 and C-reactive protein serum concentrations to predict fever, gram-negative bacteremia and complicated infection in neutropenic cancer patients. <i>Infection</i> , 1998. 26(4): p. 213-21.	Outcome is o.a. voorspellen van koorts
Engvall, P., A. Kallner, and M. Bjorkholm, Use of a novel measuring technique for the erythrocyte sedimentation rate--a pilot study in patients with neutropenia and fever. <i>Uppsala Journal of Medical Sciences</i> , 1994. 99(2): p. 187-95.	Geen 2x2 tabellen mogelijk
Engvall, P., et al., Monitoring of endotoxin, interleukin-6 and C-reactive protein serum concentrations in neutropenic patients with fever. <i>European Journal of Haematology</i> , 1995. 54(4): p. 226-34.	Geen 2x2 tabellen mogelijk

Erten, N., et al., The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients. Journal of the Chinese Medical Association: JCMA, 2004. 67(5): p. 217-21.	Geen full-text
Fleischhack, G., et al., Procalcitonin – a sensitive inflammation marker of febrile episodes in neutropenic children with cancer. Intensive Care Medicine, 2000. 26: p. S202-S211.	Kinderen
Fleischhack, G., et al., Procalcitonin in paediatric cancer patients: its diagnostic relevance is superior to that of C-reactive protein, interleukin 6, interleukin 8, soluble interleukin 2 receptor and soluble tumour necrosis factor receptor II. British Journal of Haematology, 2000. 111(4): p. 1093-102.	Kinderen
Gac, A.C., et al., Dynamics of procalcitonin and bacteremia in neutropenic adults with acute myeloid leukemia. Leukemia Research, 2011. 35(10): p. 1294-6.	Selectiecriterium primair gericht op neutropene koorts
Gafter-Gvili, A., et al., The role of 18F-FDG PET/CT for the diagnosis of infections in patients with hematological malignancies and persistent febrile neutropenia. Leukemia Research, 2013. 37(9): p. 1057-62.	Selectiecriterium primair gericht op neutropene koorts
Giamarellos-Bourboulis, E.J., et al., Assessment of procalcitonin as a diagnostic marker of underlying infection in patients with febrile neutropenia. Clinical Infectious Diseases, 2001. 32(12): p. 1718-1725.	Selectiecriterium primair gericht op neutropene koorts
Gong, Z.J., et al., Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. Oncologist, 2019. 24(7): p. 997-1007.	Vergelijking tussen patiënten met en zonder koorts
Grutzmeier, S. and H. von Schenck, C-reactive protein during chemotherapy for acute leukemia with special reference to non-infective causes of fever. Medical Oncology & Tumor Pharmacotherapy, 1986. 3(2): p. 71-5.	Niet alle patiënten hadden koorts
Gunalp, M., et al., Independent factors for prediction of poor outcomes in patients with febrile neutropenia. Medical Science Monitor, 2014. 20: p. 1826-32.	Outcome is niet diagnose van tumor- of infectiekoorts
Gunasekaran, V., et al., Serum Procalcitonin for Predicting Significant Infections and Mortality in Pediatric Oncology. Indian Pediatrics, 2016. 53(12): p. 1075-1078.	Kinderen
Gunther, G., et al., Endotoxaemia and inflammatory mediators in febrile patients with haematological disease. Journal of Internal Medicine, 1995. 237(1): p. 27-33.	Geen 2x2 tabellen mogelijk
Gupta, M., et al., Interleukin-6 versus C-reactive protein as markers for early detection of bacteremia in febrile neutropenia in pediatric population. Indian Journal of Medical and Paediatric Oncology, 2020. 41(5): p. 702-706.	Kinderen
Guy, S.D., et al., Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. European Journal of Nuclear Medicine & Molecular Imaging, 2012. 39(8): p. 1348-55.	Geen volledige 2x2 tabellen mogelijk
Ha, Y.E., et al., Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Supportive Care in Cancer, 2011. 19(11): p. 1761-7.	Selectiecriterium primair gericht op neutropene koorts
Hacifazlioglu, N.E., et al., Assessment of procalcitonin as diagnostic marker in children with neutropenic fever. Zeynep Kamil Tip Bulteni, 2016. 47(2): p. 57-62.	Kinderen
Hadi, D.A., et al., Evaluation of serum c-reactive protein and procalcitonin as diagnostic biomarkers of bacterial infection in febrile pediatric cancer patients on chemotherapy. Biochemical and Cellular Archives, 2020. 20: p. 3555-3563.	Kinderen
Haeusler, G.M., F. Carlesse, and R.S. Phillips, An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during	Kinderen

neutropenia in children with cancer. <i>Pediatric Infectious Disease Journal</i> , 2013. 32(10): p. e390-6.	
Halder, R., et al., Comparison of CRP and procalcitonin for etiological diagnosis of fever during febrile neutropenia in hematology patients- an experience from a tertiary care center in Northern India. <i>Blood Cells Molecules & Diseases</i> , 2020. 84: p. 102445.	Selectiecriterium primair gericht op neutropene koorts
Hamalainen, S., et al., Neutropenic fever and severe sepsis in adult acute myeloid leukemia (AML) patients receiving intensive chemotherapy: Causes and consequences. <i>Leukemia & Lymphoma</i> , 2008. 49(3): p. 495-501.	Geen 2x2 tabellen mogelijk
Hambach, L., et al., Diagnostic value of procalcitonin serum levels in comparison with C-reactive protein in allogeneic stem cell transplantation. <i>Haematologica</i> , 2002. 87(6): p. 643-651.	Na stamcel transplantatie
Hara, M., et al., Measurements of procalcitonin facilitate targeting of endotoxin adsorption treatment in febrile neutropenic patients suffering from shock. <i>Clinical Nephrology</i> , 2014. 81(1): p. 67-70.	Geen full-text
Hatzistilianou, M., et al., Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia. <i>Inflammation Research</i> , 2010. 59(5): p. 339-47.	Kinderen
Hazan, G., et al., Clinical and laboratory parameter dynamics as markers of blood stream infections in pediatric oncology patients with fever and neutropenia. <i>Journal of Pediatric Hematology/Oncology</i> , 2014. 36(5): p. e275-9.	Kinderen
Heinz, W.J., et al., Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2017. 96(11): p. 1775-1792.	Geen kwaliteitsbeoordeling van geïnccludeerde studies
Heney, D., et al., Interleukin-6 and its relationship to C-reactive protein and fever in children with febrile neutropenia. <i>Journal of Infectious Diseases</i> , 1992. 165(5): p. 886-90.	Kinderen
Herrmann, J.L., et al., TNF α , IL-1 β and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. <i>Infection</i> , 1994. 22(5): p. 309-315.	Geen 2x2 tabellen mogelijk
Hitoglou-Hatzi, S., et al., Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia. <i>Clinical & Experimental Medicine</i> , 2005. 5(2): p. 60-5.	Kinderen
Hong, J., et al., Pre-treatment blood inflammatory markers as predictors of systemic infection during induction chemotherapy: results of an exploratory study in patients with acute myeloid leukemia. <i>Supportive Care in Cancer</i> , 2016. 24(1): p. 187-194.	Outcome is niet diagnose van tumor- of infectiekoorts
Intke, C., et al., Interleukin-1 receptor antagonist as a biomarker of sepsis in neutropenic haematological patients. <i>European Journal of Haematology</i> , 2018. 12: p. 12.	Selectiecriterium primair gericht op neutropene koorts
Islak Mutcali, S., et al., Early Changes of Mannose-Binding Lectin, H-Ficolin, and Procalcitonin in Patients with Febrile Neutropenia: A Prospective Observational Study. <i>Turkish Journal of Haematology</i> , 2016. 33(4): p. 304-310.	Geen 2x2 tabellen mogelijk
Jabbour, J.P., et al., Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients. <i>Supportive Care in Cancer</i> , 2022. 30(5): p. 4303-4314.	Enkel onderscheid tussen gram-negatieve bloedinfecties en andere redenen voor koorts
Jimeno, A., et al., Assessment of procalcitonin as a diagnostic and prognostic marker in patients with solid tumors and febrile neutropenia. <i>Cancer</i> , 2004. 100(11): p. 2462-9.	Selectiecriterium primair gericht op neutropene koorts

Juutilainen, A., et al., Biomarkers for bacteremia and severe sepsis in hematological patients with neutropenic fever: multivariate logistic regression analysis and factor analysis. <i>Leukemia & Lymphoma</i> , 2011. 52(12): p. 2349-55.	Geen 2x2 tabellen mogelijk
Juutilainen, A., et al., Serial plasma lactate measurements in haematological patients with neutropenic fever. <i>Scandinavian Journal of Infectious Diseases</i> , 2010. 42(2): p. 102-8.	Geen 2x2 tabellen mogelijk
Kancik, E., et al., Causes of fever in patients diagnosed with cancer. <i>Family Medicine and Primary Care Review</i> , 2014. 16(2): p. 111-113.	Geen full-text
Kang, S.J., et al., Predictive Value of Procalcitonin for Bacterial Infection after Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Disease Markers</i> , 2018. 2018: p. 9120878.	Koorts na interventie
Kar, Y.D., Z.C. Özdemir, and Ö. Bör, Evaluation of febrile neutropenic attacks of pediatric hematology-oncology patients. <i>Turk Pediatri Arsivi</i> , 2017. 52(4): p. 213-220.	Kinderen
Karakurt, D.G., et al., Do proinflammatory cytokine levels predict serious complication risk of infection in pediatric cancer patients? <i>Pediatric Hematology & Oncology</i> , 2014. 31(5): p. 415-24.	Kinderen
Karan, M.A., Predictive value of higher plasma interleukin-6 levels in patients with febrile neutropenia. <i>Archives of Medical Research</i> , 2002. 33(6): p. 557-61.	Selectie criterium primair gericht op neutropene koorts
Katz, J.A., et al., Value of C-reactive protein determination in the initial diagnostic evaluation of the febrile, neutropenic child with cancer. <i>Pediatric Infectious Disease Journal</i> , 1992. 11(9): p. 708-12.	Kinderen
Kitanovski, L., et al., Diagnostic accuracy of procalcitonin and interleukin-6 values for predicting bacteremia and clinical sepsis in febrile neutropenic children with cancer. <i>European Journal of Clinical Microbiology & Infectious Diseases</i> , 2006. 25(6): p. 413-5.	Kinderen
Knoll, B.M., et al., Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma. <i>American Journal of Hematology</i> , 2019. 94(3): p. E74-E76.	Letter
Koh, K.C., et al., Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in patients with high-risk febrile neutropenia. <i>Leukemia & Lymphoma</i> , 2012. 53(10): p. 1889-95.	Geen 2x2 tabellen mogelijk
Koivula, I., et al., Elevated procalcitonin predicts Gram-negative sepsis in haematological patients with febrile neutropenia. <i>Scandinavian Journal of Infectious Diseases</i> , 2011. 43(6-7): p. 471-8.	Selectie criterium primair gericht op neutropene koorts
Kostic, I., et al., Comparison of presepsin, procalcitonin, interleukin-8 and C-reactive protein in predicting bacteraemia in febrile neutropenic adult patients with haematological malignancies. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019. 11(1).	Selectie criterium primair gericht op neutropene koorts
Lappalainen, M., et al., Novel Biomarker Candidates for Febrile Neutropenia in Hematological Patients Using Nontargeted Metabolomics. <i>Disease Markers</i> , 2018. 2018: p. 6964529.	Geen 2x2 tabellen mogelijk
Lehrnbecher, T., et al., Assessment of measuring circulating levels of interleukin-6, interleukin-8, C-reactive protein, soluble Fc gamma receptor type III, and mannose-binding protein in febrile children with cancer and neutropenia. <i>Clinical Infectious Diseases</i> , 1999. 29(2): p. 414-9.	Kinderen
Lin, S.G., et al., Role of procalcitonin in the diagnosis of severe infection in pediatric patients with fever and neutropenia—a systemic review and meta-analysis. <i>Pediatric Infectious Disease Journal</i> , 2012. 31(10): p. e182-e188.	Kinderen

Liu, X., et al., Initial procalcitonin level predicts infection and its outcome in patients with non-Hodgkin lymphoma with febrile neutropenia. <i>Leukemia & Lymphoma</i> , 2015. 56(1): p. 85-91.	Selectiecriterium primair gericht op neutropene koorts
Ly, K.H., et al., Diagnostic Value of 18F-FDG PET/CT vs. Chest-Abdomen-Pelvis CT Scan in Management of Patients with Fever of Unknown Origin, Inflammation of Unknown Origin or Episodic Fever of Unknown Origin: A Comparative Multicentre Prospective Study. <i>Journal of Clinical Medicine</i> , 2022. 11(2).	FUO, niet enkel kanker
Ma, Y., et al., Analysis of risk factors and clinical indicators in bloodstream infections among patients with hematological malignancy. <i>Cancer Management and Research</i> , 2020. 12: p. 13579-13588.	Foute uitkomsten
Macchioni, D., et al., Use of procalcitonin for the differential diagnosis of fever in cancer patients: An observational study. <i>Italian Journal of Medicine</i> , 2013. 7(3): p. 166-171.	Geen 2x2 tabellen mogelijk
Manian, F.A., A prospective study of daily measurement of C-reactive protein in serum of adults with neutropenia. <i>Clinical Infectious Diseases</i> , 1995. 21(1): p. 114-21.	Selectiecriterium primair gericht op neutropene koorts
Masago, K., et al., Infectious background of febrile advanced lung cancer patients who received chemotherapy. <i>Oncology Letters</i> , 2010. 1(5): p. 849-853.	Foute uitkomsten
Massaro, K.S.R., et al., Procalcitonin (PCT) and C-reactive Protein (CRP) as severe systemic infection markers in febrile neutropenic adults. <i>BMC Infectious Diseases</i> , 2007. 7.	Selectiecriterium primair gericht op neutropene koorts
Miedema, K.G., et al., The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia. <i>Supportive Care in Cancer</i> , 2011. 19(10): p. 1593-600.	Kinderen
Mimarođlu, E., et al., The diagnostic and prognostic value of angiopoietins compared with C-reactive protein and procalcitonin in children with febrile neutropenia. <i>Turkish Journal of Pediatrics</i> , 2017. 59(4): p. 418-425.	Kinderen
Minamishima, I., et al., Serum interleukin-6 and fever at diagnosis in children with acute leukemia. <i>American Journal of Pediatric Hematology/Oncology</i> , 1993. 15(2): p. 239-44.	Kinderen
Moustafa, R., T. Albouni, and G. Aziz, The role of procalcitonin and presepsin in the septic febrile neutropenia in acute leukemia patients. <i>PLoS ONE [Electronic Resource]</i> , 2021. 16(7): p. e0253842.	Selectiecriterium primair gericht op neutropene koorts
Murat Sedef, A., et al., Prognostic value of procalcitonin in infection-related mortality of cancer patients. <i>Journal of B.U.On.</i> , 2016. 21(3): p. 740-4.	Outcome = infection-related mortality
Mutcali, S.I., et al., Early changes of mannose-binding lectin, H-ficolin, and procalcitonin in patients with febrile neutropenia: A prospective observational study. <i>Turkish Journal of Hematology</i> , 2016. 33(4): p. 304-310.	Geen 2x2 tabellen mogelijk
Nakagawa, Y., K. Suzuki, and T. Masaoka, Evaluation of the risk factors for febrile neutropenia associated with hematological malignancy. <i>Journal of Infection & Chemotherapy</i> , 2009. 15(3): p. 174-9.	Gaat over risico op neutropene koorts
Neuenschwander, L.C., et al., Plasma levels of procalcitonin and eight additional inflammatory molecules in febrile neutropenic patients. <i>Clinics (Sao Paulo, Brazil)</i> , 2011. 66(10): p. 1699-705.	Geen 2x2 tabellen mogelijk
Nishikawa, T., et al., Serum derivative of reactive oxygen metabolites (d-ROMs) in pediatric hemato-oncological patients with neutropenic fever. <i>Pediatric Blood & Cancer</i> , 2010. 55(1): p. 91-4.	Kinderen
Odagiri, T., et al., A Multicenter Cohort Study to Explore Differentiating Factors between Tumor Fever and Infection among Advanced Cancer Patients. <i>Journal of Palliative Medicine</i> , 2019. 22(11): p. 1331-1336.	Geen 2x2 tabellen mogelijk

Offidani, M., et al., Diagnostic value of C-reactive protein in discriminating fungal from nonfungal pulmonary infiltrates in patients with hematologic malignancies. <i>Supportive Care in Cancer</i> , 2006. 14(8): p. 874-877.	Foute populatie
Omar, I.A.B., H. Jabbar Salman, and W.F. Al Tameemi, The role of estimation of procalcitonin in early diagnosis of bacteremia in febrile neutropenic patients. <i>Biochemical and Cellular Archives</i> , 2019. 19(1): p. 731-736.	Geen full-text
Ortega, M., et al., Measurement of C-reactive protein in adults with febrile neutropenia after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2004. 33(7): p. 741-744.	Geen 2x2 tabellen mogelijk
Ortega, M., et al., Prospective evaluation of procalcitonin in adults with non-neutropenic fever after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2006. 37(5): p. 499-502.	Diagnostische accuratesse enkel berekend voor invasieve aspergillose
Ozdemir, Z.C., et al., The predictive value of procalcitonin, C-reactive protein, presepsin, and soluble-triggering receptor expressed on myeloid cell levels in bloodstream infections in pediatric patients with febrile neutropenia. <i>Turkish Journal of Pediatrics</i> , 2019. 61(3): p. 359-367.	Kinderen
Pedersen, L.M. and O.J. Bergmann, Urinary albumin excretion and its relationship to C-reactive protein and proinflammatory cytokines in patients with cancer and febrile neutropenia. <i>Scandinavian Journal of Infectious Diseases</i> , 2003. 35(8): p. 491-4.	Geen 2x2 tabellen mogelijk
Penagos-Paniagua, M., et al., Usefulness of C-reactive protein in the diagnosis of bacterial infection in the pediatric patient with cancer, fever and neutropenia. <i>Boletin Medico del Hospital Infantil de Mexico</i> , 2012. 69(5): p. 376-383.	Kinderen
Persson, L., et al., Assessment of systemic inflammation markers to differentiate a stable from a deteriorating clinical course in patients with febrile neutropenia. <i>European Journal of Haematology</i> , 2005. 74(4): p. 297-303.	Outcome is niet diagnose van tumor- of infectiekoorts
Persson, L., et al., Use of inflammatory markers for early detection of bacteraemia in patients with febrile neutropenia. <i>Scandinavian Journal of Infectious Diseases</i> , 2004. 36(5): p. 365-71.	Diagnostische accuratesse enkel berekend voor non-CNS bacteriëmie
Phillips, R.S., et al., Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. <i>BMC Medicine</i> , 2012. 10: p. 6.	Kinderen
Plesko, M., et al., The role of CRP, PCT, IL-6 and presepsin in early diagnosis of bacterial infectious complications in paediatric haemato-oncological patients. <i>Neoplasma</i> , 2016. 63(5): p. 752-60.	Kinderen
Prat, C., et al., Evaluation of procalcitonin, neopterin, C-reactive protein, IL-6 and IL-8 as a diagnostic marker of infection in patients with febrile neutropenia. <i>Leukemia & Lymphoma</i> , 2008. 49(9): p. 1752-61.	Selectie criterium primair gericht op neutropene koorts
Purhonen, A.K., et al., Plasma copeptin in the assessment of febrile neutropenia. <i>Peptides</i> , 2012. 36(1): p. 129-32.	Geen 2x2 tabellen mogelijk voor CRP
Rabon, P.G. and K.M. Murray, Role of nonsteroidal antiinflammatory drugs in the differential diagnosis of neoplastic fevers versus fevers of infectious etiology. <i>Journal of Pharmacy Technology</i> , 1995. 11(5): p. 211-213.	Narrative review
Richter, M.E., et al., Biomarker candidates for the detection of an infectious etiology of febrile neutropenia. <i>Infection</i> , 2016. 44(2): p. 175-86.	Selectie criterium primair gericht op neutropene koorts

Riikonen, P., et al., Cytokine and acute-phase reactant levels in serum of children with cancer admitted for fever and neutropenia. <i>Journal of Infectious Diseases</i> , 1992. 166(2): p. 432-6.	Kinderen
Riikonen, P., et al., Fever and neutropenia in children with cancer: diagnostic parameters at presentation. <i>Acta Paediatrica</i> , 1993. 82(3): p. 271-5.	Kinderen
Rintala, E., et al., Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. <i>Scandinavian Journal of Infectious Diseases</i> , 1995. 27(1): p. 39-43.	Geen full-text
Rintala, E., K. Irjala, and J. Nikoskelainen, Value of measurement of C-reactive protein in febrile patients with hematological malignancies. <i>European Journal of Clinical Microbiology & Infectious Diseases</i> , 1992. 11(11): p. 973-8.	Geen 2x2 tabellen mogelijk
Rintala, E.M. and T.J. Nevalainen, Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy. <i>European Journal of Haematology</i> , 1993. 50(1): p. 11-6.	Geen 2x2 tabellen mogelijk
Rolston, K.V., Neoplastic fever: all who shiver are not infected. <i>Supportive Care in Cancer</i> , 2005. 13(11): p. 863-4.	Editorial
Ruokonen, E., et al., Procalcitonin concentrations in patients with neutropenic fever. <i>European Journal of Clinical Microbiology & Infectious Diseases</i> , 1999. 18(4): p. 283-5.	Selectie criterium primair gericht op neutropene koorts
Sandri, M.T., et al., Procalcitonin as a useful marker of infection in hemato-oncological patients with fever. <i>Anticancer Research</i> , 2008. 28(5B): p. 3061-5.	Selectie criterium primair gericht op neutropene koorts
Santolaya, M.E., et al., Predictors of severe sepsis not clinically apparent during the first twenty-four hours of hospitalization in children with cancer, neutropenia, and fever: a prospective, multicenter trial. <i>Pediatric Infectious Disease Journal</i> , 2008. 27(6): p. 538-43.	Kinderen
Santolaya, M.E., et al., Prospective evaluation of a model of prediction of invasive bacterial infection risk among children with cancer, fever, and neutropenia. <i>Clinical Infectious Diseases</i> , 2002. 35(6): p. 678-83.	Kinderen
Santolaya, M.E., et al., Prospective validation of a risk prediction model for severe sepsis in children with cancer and high-risk febrile neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2013. 32(12): p. 1318-1323.	Kinderen
Santolaya, M.E., et al., Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. <i>Journal of Clinical Oncology</i> , 2001. 19(14): p. 3415-21.	Kinderen
Santolaya, M.E., J. Cofre, and V. Beresi, C-reactive protein: a valuable aid for the management of febrile children with cancer and neutropenia. <i>Clinical Infectious Diseases</i> , 1994. 18(4): p. 589-95.	Kinderen
Schuttrumpf, S., et al., Utility of procalcitonin concentration in the evaluation of patients with malignant diseases and elevated C-reactive protein plasma concentrations. <i>Clinical Infectious Diseases</i> , 2006. 43(4): p. 468-73.	Niet alle patiënten hadden koorts
Secmeer, G., et al., Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia. <i>Journal of Pediatric Hematology/Oncology</i> , 2007. 29(2): p. 107-11.	Kinderen
Sedef, A.M., et al., Prognostic value of procalcitonin in infection-related mortality of cancer patients. <i>Journal of B.U.ON.</i> , 2016. 21(3): p. 740-744.	Outcome = infection-related mortality
Semeraro, M., et al., A predictor of unfavourable outcome in neutropenic paediatric patients presenting with fever of unknown origin. <i>Pediatric Blood & Cancer</i> , 2010. 54(2): p. 284-90.	Kinderen

Sheng, Z.K., et al., Utility of fluorodeoxyglucose positron emission tomography/computed tomography in patients with fever of unknown origin diagnosed as lymphoma. <i>Medical Principles & Practice</i> , 2014. 23(5): p. 437-42.	Foute populatie
Shokripour, M., et al., Diagnostic accuracy of immunologic biomarkers for accurate diagnosis of bloodstream infection in patients with malignancy: Procalcitonin in comparison with C-reactive protein. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2020. 2020.	91% kinderen
Shomali, W., et al., Can procalcitonin distinguish infectious fever from tumor-related fever in non-neutropenic cancer patients? <i>Cancer</i> , 2012. 118(23): p. 5823-9.	Enkel onderscheid tussen bloedinfecties en andere redenen voor koorts
Sklavou, R., et al., Variation of serum C-reactive protein (CRP) over time in pediatric cancer patients with febrile illness and its relevance to identified pathogen. <i>Clinical Biochemistry</i> , 2012. 45(15): p. 1178-82.	Kinderen
Sodhi, K.S., et al., Rapid lung MRI - paradigm shift in evaluation of febrile neutropenia in children with leukemia: a pilot study. <i>Leukemia & Lymphoma</i> , 2016. 57(1): p. 70-5.	Kinderen
Spasova, M.I., et al., Interleukin-6, interleukin-8, interleukin-10, and C-reactive protein in febrile neutropenia in children with malignant diseases. <i>Folia Medica (Plovdiv)</i> , 2005. 47(3-4): p. 46-52.	Kinderen
Spasova, M.I., et al., Risk index score for bacteremia in febrile neutropenic episodes in children with malignancies. <i>Journal of B.U.On.</i> , 2009. 14(3): p. 411-8.	Kinderen
Stabell, N., et al., Febrile neutropenia in children with cancer: A retrospective Norwegian multicentre study of clinical and microbiological outcome. <i>Scandinavian Journal of Infectious Diseases</i> , 2008. 40(4): p. 301-307.	Kinderen
Starke, I.D., et al., Serum C-reactive protein levels in the management of infection in acute leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1984. 20(3): p. 319-25.	Geen 2x2 tabellen mogelijk
Stryjewski, G.R., et al., Interleukin-6, interleukin-8, and a rapid and sensitive assay for calcitonin precursors for the determination of bacterial sepsis in febrile neutropenic children. <i>Pediatric Critical Care Medicine</i> , 2005. 6(2): p. 129-135.	Kinderen
Sudhoff, T., A. Giagounidis, and M. Karthaus, Serum and plasma parameters in clinical evaluation of neutropenic fever. <i>Antibiotics & Chemotherapy</i> , 2000. 50: p. 10-9.	Narrative review
Timonen, T.T. and P. Koistinen, C-reactive protein for detection and follow-up of bacterial and fungal infections in severely neutropenic patients with acute leukaemia. <i>European Journal of Cancer & Clinical Oncology</i> , 1985. 21(5): p. 557-62.	Geen 2x2 tabellen mogelijk
Tsavaris, N., et al., The response of paraneoplastic fever of lymphomas and solid tumours to the administration of naproxen. <i>Journal of Internal Medicine</i> , 1991. 230(6): p. 549-50.	Geen full-text
Ukale, V., et al., Inflammatory parameters after pleurodesis in recurrent malignant pleural effusions and their predictive value. <i>Respiratory Medicine</i> , 2004. 98(12): p. 1166-72.	Foute populatie
Urbonas, V., A. Eidukaite, and I. Tamuliene, The predictive value of soluble biomarkers (CD14 subtype, interleukin-2 receptor, human leucocyte antigen-G) and procalcitonin in the detection of bacteremia and sepsis in pediatric oncology patients with chemotherapy-induced febrile neutropenia. <i>Cytokine</i> , 2013. 62(1): p. 34-7.	Kinderen
Uys, A., et al., Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. <i>European Journal of Cancer Care</i> , 2007. 16(6): p. 475-83.	Outcome is niet diagnose van tumor- of infectiekoorts

Vanderschueren, S., et al., Lack of value of the naproxen test in the differential diagnosis of prolonged febrile illnesses. <i>American Journal of Medicine</i> , 2003. 115(7): p. 572-5.	FUO, niet enkel kanker
Vanska, M., et al., IL-10 combined with procalcitonin improves early prediction of complications of febrile neutropenia in hematological patients. <i>Cytokine</i> , 2012. 60(3): p. 787-92.	Selectie criterium primair gericht op neutropene koorts
von Lilienfeld-Toal, M., et al., Change of procalcitonin predicts clinical outcome of febrile episodes in patients with hematological malignancies. <i>Supportive Care in Cancer</i> , 2006. 14(12): p. 1241-5.	Outcome is niet diagnose van tumor- of infectiekoorts
Von Lilienfeld-Toal, M., et al., Markers of bacteremia in febrile neutropenic patients with hematological malignancies: Procalcitonin and IL-6 are more reliable than C-reactive protein. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2004. 23(7): p. 539-544.	Selectie criterium primair gericht op neutropene koorts
Vos, F.J., C.P. Bleeker-Rovers, and W.J. Oyen, The use of FDG-PET/CT in patients with febrile neutropenia. <i>Seminars in Nuclear Medicine</i> , 2013. 43(5): p. 340-8.	Enkel gezocht in PubMed, geen kwaliteitsbeoordeling van geïnccludeerde studies
Vyles, D., et al., Procalcitonin as a Marker of Bacteremia in Patients With Fever and Acute Lymphoblastic Leukemia. <i>Pediatric Emergency Care</i> , 2016. 32(9): p. 590-3.	Kinderen
Walker, H., et al., Non-neutropenic fever in children with cancer: Management, outcomes and clinical decision rule validation. <i>Pediatric Blood and Cancer</i> , 2022. 69(12).	Kinderen
Wang, S.S., et al., The clinical utility of fluorodeoxyglucose-positron emission tomography for investigation of fever in immunocompromised children. <i>Journal of Paediatrics & Child Health</i> , 2018. 54(5): p. 487-492.	Kinderen
Wei, W. and L. Hesheng, Malignancy in Chinese adults presenting as fever of unknown origin. <i>International Journal of Clinical Practice</i> , 2003. 57(6): p. 508-512.	Geen full-text
Xia, T., et al., Comparison of the diagnostic power of cytokine patterns and procalcitonin for predicting infection among paediatric haematology/oncology patients. <i>Clinical Microbiology & Infection</i> , 2016. 22(12): p. 996-1001.	Kinderen
Xu, X.J., et al., Comparison of interleukin-6, interleukin-10, procalcitonin and C-reactive protein in identifying high-risk febrile illness in pediatric cancer patients: A prospective observational study. <i>Cytokine</i> , 2019. 116: p. 1-6.	Kinderen
Yaegashi, H., et al., Differential diagnosis between bacterial infection and neoplastic fever in patients with advanced urological cancer: the role of procalcitonin. <i>International Journal of Urology</i> , 2014. 21(1): p. 104-6.	Geen 2x2 tabellen mogelijk
Yang, M., et al., Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies. <i>PLoS ONE [Electronic Resource]</i> , 2019. 14(12): p. e0225765.	Enkel onderscheid tussen bacteriëmie en geen bacteriëmie
Yetkin, F., et al., The evaluation of procalcitonin as a diagnostic and prognostic marker of bacterial infections in febrile neutropenic patients. <i>Klimik Dergisi</i> , 2011. 24(1): p. 24-30.	Turks
Yonemori, K., et al., Clinical value of serial measurement of serum C-reactive protein level in neutropenic patients. <i>Leukemia & Lymphoma</i> , 2001. 41(5-6): p. 607-14.	Selectie criterium primair gericht op neutropene koorts
Zell, J.A. and J.C. Chang, Neoplastic fever: a neglected paraneoplastic syndrome. <i>Supportive Care in Cancer</i> , 2005. 13(11): p. 870-7.	Narrative review
Zhang, Q., et al., Clinical value of dual-phase 18F-FDG SPECT with serum procalcitonin for identification of etiology in tumor patients with fever of unknown origin. <i>Asian Pacific Journal of Cancer Prevention: Apjcp</i> , 2014. 15(2): p. 683-6.	FUO, niet enkel kanker

Onderzoeksvraag 2 (module Symptomatische medicamenteuze behandeling)

Wat is het effect van medicamenteuze behandeling op patiënten met tumorkoorts in de palliatieve fase?

PICO

Patients/Patiënten	Patiënten met tumorkoorts in de palliatieve fase
Intervention/Interventie	Medicamenteuze behandeling (paracetamol, NSAID, corticosteroïden)
Comparison/Vergelijking	Behandelingen onderling, andere behandeling, geen behandeling, placebo
Outcome(s)/Uitkomst(en)	Cruciaal: koorts, bijwerkingen Belangrijk: kwaliteit van leven

Zoekstrategie

OVID Medline (R): 1946 to December 13, 2022

- 1 fever/ or "fever of unknown origin"/ (46988)
- 2 fever\$.mp. (223267)
- 3 FUO.mp. (773)
- 4 or/1-3 (223282)
- 5 exp Neoplasms/ (3770900)
- 6 Neoplasm Staging/ (190952)
- 7 cancer\$.ti,ab. (1827156)
- 8 tumor\$.ti,ab. (1460427)
- 9 tumour\$.ti,ab. (270897)
- 10 carcinoma\$.ti,ab. (651181)
- 11 neoplas\$.ti,ab. (257341)
- 12 lymphoma.ti,ab. (158695)
- 13 melanoma.ti,ab. (113505)
- 14 staging.ti,ab. (78827)
- 15 metastas\$.ti,ab. (357972)
- 16 metastatic.ti,ab. (227113)
- 17 exp Neoplasm Metastasis/ (220007)
- 18 exp neoplastic processes/ (508061)
- 19 neoplastic process\$.ti,ab. (2882)
- 20 non small cell.ti,ab. (63965)
- 21 adenocarcinoma\$.ti,ab. (146281)
- 22 squamous cell.ti,ab. (107133)
- 23 nsclc.ti,ab. (43941)
- 24 osteosarcoma\$.ti,ab. (23629)
- 25 phyllodes.ti,ab. (1903)
- 26 cystosarcoma\$.ti,ab. (569)
- 27 fibroadenoma\$.ti,ab. (3570)
- 28 (non adj small adj cell).ti,ab. (63965)
- 29 (non adj2 small adj2 cell).ti,ab. (64209)
- 30 (nonsmall adj2 cell).ti,ab. (3064)
- 31 plasmacytoma\$.ti,ab. (6215)
- 32 myeloma.ti,ab. (52176)
- 33 multiple myeloma.ti,ab. (37694)
- 34 lymphoblastoma\$.ti,ab. (345)
- 35 lymphocytoma\$.ti,ab. (335)
- 36 lymphosarcoma\$.ti,ab. (4074)
- 37 immunocytoma.ti,ab. (404)
- 38 sarcoma\$.ti,ab. (93787)
- 39 hodgkin\$.ti,ab. (63811)

40 (nonhodgkin\$ or non hodgkin\$.ti,ab. (36844)
 41 malignan\$.ti,ab. (570610)
 42 exp Paraneoplastic Syndromes/ (33764)
 43 or/5-42 (4495619)
 44 4 and 43 (31506)
 45 exp Anti-Inflammatory Agents, Non-Steroidal/ (212844)
 46 NSAID*.mp. (25663)
 47 paracetamol.mp. or exp Acetaminophen/ (24437)
 48 dafalgan.mp. (12)
 49 Adrenocorticotrophic Hormone/ (49603)
 50 exp Adrenal Cortex Hormones/ (420382)
 51 exp Steroids/ (911671)
 52 (prednisone\$ or prednisolone\$ or dexamethasone\$ or corticosteroid\$.mp. (253767)
 53 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 (1305848)
 54 44 and 53 (3268)
 55 randomized controlled trial.pt. (582663)
 56 controlled clinical trial.pt. (95117)
 57 randomized.ab. (514123)
 58 placebo.ab. (214631)
 59 clinical trials as topic.sh. (200671)
 60 randomly.ab. (338211)
 61 trial.ti. (242742)
 62 55 or 56 or 57 or 58 or 59 or 60 or 61 (1347804)
 63 exp animals/ not humans.sh. (5074766)
 64 62 not 63 (1228612)
 65 meta-analysis.mp,pt. or review.pt. or search:.tw. (3173471)
 66 64 or 65 (4188756)
 67 54 and 66 (730)

OVID Medline (R) Epub Ahead of Print <December 13, 2022>, Ovid MEDLINE(R) Daily Update
 <December 13, 2022>

1 fever/ or "fever of unknown origin"/ (85)
 2 fever\$.mp. (2304)
 3 FUO.mp. (15)
 4 or/1-3 (2304)
 5 exp Neoplasms/ (7495)
 6 Neoplasm Staging/ (140)
 7 cancer\$.ti,ab. (32083)
 8 tumor\$.ti,ab. (20068)
 9 tumour\$.ti,ab. (2736)
 10 carcinoma\$.ti,ab. (7640)
 11 neoplas\$.ti,ab. (3266)
 12 lymphoma.ti,ab. (2100)
 13 melanoma.ti,ab. (1497)
 14 staging.ti,ab. (1313)
 15 metastas\$.ti,ab. (5421)
 16 metastatic.ti,ab. (3480)
 17 exp Neoplasm Metastasis/ (147)
 18 exp neoplastic processes/ (685)
 19 neoplastic process\$.ti,ab. (25)
 20 non small cell.ti,ab. (1312)
 21 adenocarcinoma\$.ti,ab. (2066)
 22 squamous cell.ti,ab. (1861)

- 23 nsccl.ti,ab. (953)
 24 osteosarcoma\$.ti,ab. (296)
 25 phyllodes.ti,ab. (23)
 26 cystosarcoma\$.ti,ab. (2)
 27 fibroadenoma\$.ti,ab. (73)
 28 (non adj small adj cell).ti,ab. (1312)
 29 (non adj2 small adj2 cell).ti,ab. (1315)
 30 (nonsmall adj2 cell).ti,ab. (49)
 31 plasmacytoma\$.ti,ab. (49)
 32 myeloma.ti,ab. (633)
 33 multiple myeloma.ti,ab. (569)
 34 lymphoblastoma\$.ti,ab. (0)
 35 lymphocytoma\$.ti,ab. (6)
 36 lymphosarcoma\$.ti,ab. (1)
 37 immunocytoma.ti,ab. (1)
 38 sarcoma\$.ti,ab. (1036)
 39 hodgkin\$.ti,ab. (565)
 40 (nonhodgkin\$ or non hodgkin\$).ti,ab. (344)
 41 malignan\$.ti,ab. (8131)
 42 exp Paraneoplastic Syndromes/ (28)
 43 or/5-42 (52395)
 44 4 and 43 (275)
 45 exp Anti-Inflammatory Agents, Non-Steroidal/ (236)
 46 NSAID*.mp. (430)
 47 paracetamol.mp. or exp Acetaminophen/ (177)
 48 dafalgan.mp. (1)
 49 Adrenocorticotrophic Hormone/ (14)
 50 exp Adrenal Cortex Hormones/ (352)
 51 exp Steroids/ (934)
 52 (prednisone\$ or prednisolone\$ or dexamethasone\$ or corticosteroid\$.mp. (2679)
 53 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 (4272)
 54 44 and 53 (20)
 55 randomized controlled trial.pt. (1388)
 56 controlled clinical trial.pt. (24)
 57 randomized.ab. (10743)
 58 placebo.ab. (2777)
 59 clinical trials as topic.sh. (63)
 60 randomly.ab. (5361)
 61 trial.ti. (5488)
 62 55 or 56 or 57 or 58 or 59 or 60 or 61 (18231)
 63 exp animals/ not humans.sh. (5899)
 64 62 not 63 (18006)
 65 meta-analysis.mp,pt. or review.pt. or search:.tw. (65031)
 66 64 or 65 (78998)
 67 54 and 66 (5)

Embase

#1.	'fever'/exp	309565
#2.	'pyrexia idiopathica'/exp	6773
#3.	fever*:ti,ab	284202
#4.	fuo:ti,ab	1522

#5.	#1 OR #2 OR #3 OR #4	454385
#6.	'neoplasm'/exp	5828741
#7.	'cancer staging'/exp	425801
#8.	cancer*:ti,ab	3034517
#9.	tumor*:ti,ab	2299852
#10.	tumour*:ti,ab	422705
#11.	carcinoma*:ti,ab	1009800
#12.	lymphoma:ti,ab	267044
#13.	melanoma:ti,ab	182037
#14.	staging:ti,ab	148042
#15.	metastatic:ti,ab	422780
#16.	'metastasis'/exp	781398
#17.	'oncogenesis and malignant transformation'/exp	1184938
#18.	neoplastic AND process*:ti,ab	17682
#19.	(non NEAR/1 small NEAR/1 cell):ti,ab	126104
#20.	adenocarcinoma*:ti,ab	259577
#21.	(squamous NEAR/1 cell):ti,ab	174436
#22.	nsclc:ti,ab	103023
#23.	osteosarcoma*:ti,ab	35253
#24.	phyllodes:ti,ab	2998
#25.	cystosarcoma*:ti,ab	685
#26.	fibroadenoma*:ti,ab	5479
#27.	(non NEAR/2 small NEAR/2 cell):ti,ab	126348
#28.	(nonsmall NEAR/2 cell):ti,ab	105164
#29.	plasmacytoma*:ti,ab	8761
#30.	myeloma:ti,ab	97765
#31.	(multiple NEAR/1 myeloma):ti,ab	77060
#32.	lymphoblastoma*:ti,ab	346
#33.	lymphocytoma*:ti,ab	432
#34.	lymphosarcoma*:ti,ab	4586
#35.	immunocytoma:ti,ab	472
#36.	sarcoma*:ti,ab	137001
#37.	hodgkin*:ti,ab	104118
#38.	nonhodgkin*:ti,ab OR ((non NEAR/1 hodgkin*):ti,ab)	62005
#39.	malignan*:ti,ab	953232
#40.	'paraneoplastic syndrome'/exp	49354
#41.	#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40	6935917
#42.	'nonsteroid antiinflammatory agent'/exp	1206183
#43.	nsai*:ti,ab	50585
#44.	paracetamol:ti,ab	21858
#45.	'paracetamol'/exp	107929

#46.	dafalgan:ti,ab	19
#47.	'corticotropin'/exp	77227
#48.	'corticosteroid'/exp	1139948
#49.	'steroid'/exp	1844919
#50.	prednisone*:ti,ab OR prednisolone*:ti,ab OR dexamethasone*:ti,ab OR corticosteroid*:ti,ab	348620
#51.	#42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50	2815949
#52.	#5 AND #41 AND #51	38308
#53.	#5 AND #41 AND #51 AND ([cochrane review]/lim OR [systematic review]/lim OR [meta analysis]/lim OR [randomized controlled trial]/lim) AND ([article]/lim OR [article in press]/lim OR [review]/lim) AND ([dutch]/lim OR [english]/lim) AND ([embase]/lim OR [pubmed-not-medline]/lim)	1639

Cochrane Library

#1	MeSH descriptor: [Fever] explode all trees	2223
#2	MeSH descriptor: [Fever of Unknown Origin] explode all trees	67
#3	fever*:ti,ab	15335
#4	FUO:ti,ab	58
#5	{or #1-#4}	16292
#6	MeSH descriptor: [Neoplasms] explode all trees	90536
#7	MeSH descriptor: [Neoplasm Staging] explode all trees	6886
#8	cancer*:ti,ab	167181
#9	tumor*:ti,ab	61672
#10	tumour*:ti,ab	13784
#11	carcinoma*:ti,ab	33567
#12	neoplasm*:ti,ab	7823
#13	lymphoma:ti,ab	10169
#14	melanoma:ti,ab	5692
#15	staging:ti,ab	5718
#16	metastas*:ti,ab	20116
#17	metastatic:ti,ab	31362
#18	MeSH descriptor: [Neoplasm Metastasis] explode all trees	5515
#19	MeSH descriptor: [Neoplastic Processes] explode all trees	10538
#20	neoplastic process*:ti,ab	181
#21	(non NEAR small NEAR cell):ti,ab	12895
#22	adenocarcinoma*:ti,ab	9214
#23	(squamous NEAR cell):ti,ab	8100
#24	nsclc:ti,ab	10868
#25	osteosarcoma*:ti,ab	472
#26	phylloides:ti,ab	4
#27	cystosarcoma*:ti,ab	0
#28	fibroadenoma*:ti,ab	91
#29	(non NEAR/2 small NEAR/2 cell):ti,ab	12868
#30	(nonsmall NEAR/2 cell):ti,ab	10138
#31	plasmacytoma*:ti,ab	112
#32	myeloma:ti,ab	5930
#33	(multiple NEAR myeloma):ti,ab	5372
#34	lymphoblastoma*:ti,ab	0
#35	lymphocytoma*:ti,ab	1
#36	lymphosarcoma*:ti,ab	23
#37	immunocytoma:ti,ab	16

#38	sarcoma*:ti,ab	2631
#39	hodgkin*:ti,ab	5532
#40	(nonhodgkin* or (non NEAR hodgkin*)):ti,ab	3344
#41	malignan*:ti,ab	27963
#42	MeSH descriptor: [Paraneoplastic Syndromes] explode all trees	313
#43	{or #6-#42}	257834
#44	#5 AND #43	3232
#45	MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees	7933
#46	NSAI*:ti,ab	7716
#47	paracetamol:ti,ab	5657
#48	MeSH descriptor: [Acetaminophen] explode all trees	3522
#49	dafalgan:ti,ab	5
#50	MeSH descriptor: [Adrenocorticotrophic Hormone] explode all trees	1477
#51	MeSH descriptor: [Adrenal Cortex Hormones] explode all trees	15369
#52	MeSH descriptor: [Steroids] explode all trees	63171
#53	(prednisone* or prednisolone* or dexamethasone* or corticosteroid*):ti,ab	45465
#54	{or #45-#53}	114803
#55	#44 AND #54	279

Tabel 1. Resultaten van zoekactie van onderzoeksvraag 4

Database	Aantal
Medline	730
PreMedline	5
Embase	1639
CDSR	9
CENTRAL	270
Totaal aantal resultaten	2653
Aantal geëxcludeerd (dubbelen en foute taal)	333
Totaal aantal unieke resultaten	2320

Tabel 2. Overzicht van geëxcludeerde studies gebaseerd op beoordeling van de volledige tekst van onderzoeksvraag 4

Referentie	Reden voor exclusie
Honarmand, H., et al., Randomized trial of the effect of intravenous paracetamol on inflammatory biomarkers and outcome in febrile critically ill adults. DARU, Journal of Pharmaceutical Sciences, 2012. 20(1)	Geen tumorkoorts
Oborilova, A., et al., Symptomatic intravenous antipyretic therapy: efficacy of metamizol, diclofenac, and propacetamol. Journal of Pain & Symptom Management, 2002. 24(6): p. 608-15	Aandeel tumorkoorts onduidelijk en <50%
Reymond, D., et al., Antipyretic effect of parenteral paracetamol (propacetamol) in pediatric oncologic patients: a randomized trial. Pediatric Hematology & Oncology, 1997. 14(1): p. 51-7	Kinderen
Weinkove, R., et al., A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients. Leukemia & Lymphoma, 2019. 60(6): p. 1540-1547	Aandeel tumorkoorts onduidelijk
Bijlage GRADE profielen (per onderzoeksvraag op te stellen; export vanuit GRADEpro)	